SBIR-STTR Award

Validating novel DNA repair deficient cancer therapy targets and small molecule compounds
Award last edited on: 2/21/2023

Sponsored Program
STTR
Awarding Agency
NIH : NCI
Total Award Amount
$398,917
Award Phase
1
Solicitation Topic Code
396
Principal Investigator
Steven M Lipkin

Company Information

Ananeo Therapeutics Inc

885 3rd Avenue Fl 20
New York, NY 10022
   (646) 962-6303
   N/A
   N/A

Research Institution

Weill Medical College of Cornell University

Phase I

Contract Number: 1R41CA275627-01
Start Date: 9/1/2022    Completed: 8/31/2023
Phase I year
2022
Phase I Amount
$398,917
Single-strand DNA repair (ssDR) is critical for preventing genomic catastrophe. AnaNeo Therapeutics wasfounded by experts in DNA repair mechanisms. Extending our team's previous fundamental ssDR studies weanalyzed >61,000 tumors for somatic mutations, generated isogenic mutant/wild-type cell line pairs, screenedtwo isogenic cell line pairs with small molecule libraries, performed computational and experimental syntheticlethality (SL) screens and used state-of-the-art Schrodinger Maestro drug docking software to nominate smallmolecule ssDR SL hits. Here in this Phase I STTR project we propose to validate candidate targets and smallmolecule inhibitors. Overall, this study will nominate innovative ssDR SL precision therapy targets and smallmolecule hits for lead optimization in future Phase II SBIR studies.

Public Health Relevance Statement:
Single-strand DNA repair is critical for preventing genomic catastrophe. We have screened drug and gene mutation libraries to identify novel cancer therapy compounds for tumors that carry DNA repair mutations. This study will validate innovative precision cancer therapy targets to help patients whose tumors carry DNA repair mutations.

Project Terms:

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----
© Copyright 1983-2024  |  Innovation Development Institute, LLC   |  Swampscott, MA  |  All Rights Reserved.